The latest clinical research trial data of sunitinib

Sunitinib, as a classic targeted anti-cancer drug, has been on the market for many years, but its research continues to advance globally, especially in terms of combined immunotherapy, different dosage regimens, analysis of resistance mechanisms, and expansion of new indications, showing new research value. According to the latest information released by European and American multi-center tumor research platforms, multiple ongoing clinical trials are trying to improve their competitiveness in the era of precision medicine through strategic optimization.

One of the most high-profile studies in recent years is the combination of sunitinib and immune checkpoint inhibitors. For example, in the treatment of metastatic renal cell carcinoma (RCC), researchers are trying to combine sunitinib with PD-1/PD-L1 antibody drugs to exert a synergistic anti-tumor effect. Some trial results show that the combination group has certain advantages in progression-free survival, and the side effect spectrum has different compositions. Although it has not yet become a standard treatment, it provides a theoretical basis for future combination treatment directions.

In addition to the combined use of drugs, researchers are also exploring the impact of different dosages and cycles of sunitinib on the efficacy and tolerability. Some emerging strategies suggest the use of alternative programs such as "2 weeks of medication + 1 week of drug withdrawal" or "4 weeks of medication + 2 weeks of drug withdrawal" to reduce toxic and side effects while maintaining drug efficacy. Such studies are welcomed by clinicians and patients, especially in individuals who are less tolerant to standard regimens.

In addition, the resistance mechanism of sunitinib has also become a research hotspot. It is currently believed that its drug resistance mainly involves the activation of alternative angiogenic pathways in tumor cells and changes in the immunosuppressive state of the microenvironment. Some cutting-edge studies have attempted to intervene in the resistance process by combining other target inhibitors or immunomodulatory drugs, and have achieved initial results.

Reference materials:https://www.sutent.com/